Opium (Opioid) Addiction Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Opium Addiction Clinical Trials Market Report Overview
The Opium (Opioid) Addiction clinical trial market research report provides an overview of the Opium (Opioid) Addiction clinical trials scenario. The report provides top-line data relating to the clinical trials on Opium (Opioid) Addiction. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Opium (Opioid) Addiction Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Opium (Opioid) Addiction clinical trials market are North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America, among others. North America dominates the market.
In a country-wise analysis, as of April 2022, the US has the highest number of Opium (Opioid) Addiction clinical trials, followed by Iran, Australia, the UK, Canada, China, Germany, Russia, Sweden, and Malaysia.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the US has the highest proportion of Opium (Opioid) Addiction to Central Nervous System clinical trials as of April 2022. Moreover, most of the clinical trials were conducted in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Opium (Opioid) Addiction to Central Nervous System clinical trials as of April 2022. Out of all the clinical trials conducted in the E7 countries, the majority were in China.
Opium (Opioid) Addiction Clinical Trials Analysis by Regions
For more regional insights into the Opium (Opioid) Addiction clinical trials market, download a free report sample
Opium (Opioid) Addiction Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Opium (Opioid) Addiction clinical trials market are institution, company, and the government. Out of them, institution dominates the market, followed by company.
Opium (Opioid) Addiction Clinical Trials Market Analysis by Sponsor Types
For more sponsor type insights into the Opium (Opioid) Addiction clinical trials market, download a free report sample
Opium (Opioid) Addiction Clinical Trials Market - Competitive Landscape
The leading sponsors in the Opium (Opioid) Addiction clinical trials market are Indivior Plc, Alkermes Plc, Novo Holdings AS, Orexo AB, Titan Pharmaceuticals Inc, Mundipharma International Ltd, Collegium Pharmaceutical Inc, Novartis AG, Pfizer Inc, and Emmes Co LLC. Out of them, Indivior Plc has conducted the highest number of Opium (Opioid) Addiction clinical trials.
Opium (Opioid) Addiction Clinical Trials Market Analysis by Sponsors
To know more about the leading players in the Opium (Opioid) Addiction clinical trials market, download a free report sample
Opium (Opioid) Addiction Clinical Trials Market Report Overview
Key Regions | North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America |
Key Countries | The US, Iran, Australia, the UK, Canada, China, Germany, Russia, Sweden, and Malaysia |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Indivior Plc, Alkermes Plc, Novo Holdings AS, Orexo AB, Titan Pharmaceuticals Inc, Mundipharma International Ltd, Collegium Pharmaceutical Inc, Novartis AG, Pfizer Inc, and Emmes Co LLC |
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type and end point status
- The report reviews top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with reason for unaccomplishment
- The report provides enrollment trends for the past five years
- Report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Alkermes Plc
Novo Holdings AS
Orexo AB
Titan Pharmaceuticals Inc
Mundipharma International Ltd
Collegium Pharmaceutical Inc
Novartis AG
Pfizer Inc
Emmes Co LLC
Table of Contents
Frequently asked questions
-
What are the key regions in the Opium (Opioid) Addiction clinical trials market?
The key regions in the Opium (Opioid) Addiction clinical trials market are North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America, among others.
-
What are the key countries in the Opium (Opioid) Addiction clinical trials market?
The key countries in the Opium (Opioid) Addiction clinical trials market are the US, Iran, Australia, the UK, Canada, China, Germany, Russia, Sweden, and Malaysia.
-
What are the key sponsor types in the Opium (Opioid) Addiction clinical trials market?
The key sponsor types in the Opium (Opioid) Addiction clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the Opium (Opioid) Addiction clinical trials market?
The leading sponsors in the Opium (Opioid) Addiction clinical trials market are Indivior Plc, Alkermes Plc, Novo Holdings AS, Orexo AB, Titan Pharmaceuticals Inc, Mundipharma International Ltd, Collegium Pharmaceutical Inc, Novartis AG, Pfizer Inc, and Emmes Co LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Central Nervous System reports

